No difference in function between stem cells and control during microfracture
Transplantation of autologous bone marrow-derived mesenchymal stem cells under arthroscopic surgery with microfracture versus microfracture alone for articular cartilage lesions in the knee: A multicenter prospective randomized control clinical trial
Regen Ther. 2019;(11):106-113. doi: 10.1016/j.reth.2019.06.002The authors randomized 14 patients who were undergoing microfracture to two groups: one group received bone marrow-derived mesenchymal stem cells (BMSCs), and the other group were controls. Outcomes included the Knee Injury and Osteoarthritis Outcome Score (KOOS), the International Knee Documentation Committee (IKDC), T2 time on magnetic resonance imaging, and the Magnetic Resonance Observation Cartilage Repair Tissue (MOCART) scoring system. Scores were collected at 6, 12, 24 and 48 weeks after surgery. There was no significant difference on most functional outcome scores or T2 values between the two groups. The intervention group did have significantly higher (better) MOCART scores at 24 and 48 weeks post-operative.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
